Magnevist

Gadopentetate dimeglumine, the active ingredient in Magnevist, is a gadolinium‑based contrast agent presented as a sterile solution for injection for intravenous use. It shortens T1 relaxation time of nearby water protons, thereby enhancing signal intensity on magnetic resonance imaging and facilitating diagnostic evaluation of vascular and tissue structures.

GNH USA supplies Magnevist as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, imaging centres and clinics worldwide, providing reliable access to this essential diagnostic imaging agent and supporting patient care pathways.

Magnevist (gadopentetate dimeglumine) is used as a contrast agent in magnetic resonance imaging to improve visualization of anatomical structures. - Central nervous system imaging: enhances delineation of lesions, tumors, and vascular abnormalities in brain and spinal cord MRI. - Cardiovascular imaging: improves visualization of cardiac chambers, vessels, and perfusion during cardiac MRI. - Abdominal and pelvic imaging: provides better contrast of liver, kidneys, and pelvic organs for lesion detection. - MR angiography: facilitates high‑resolution depiction of arterial and venous structures without ionizing radiation. - Musculoskeletal imaging: highlights joint, bone, and soft‑tissue pathology for more accurate assessment.

Adverse reactions to Magnevist may occur after intravenous administration.

Common Side Effects: - Nausea: mild and transient. - Headache: occasional discomfort. - Injection site discomfort: mild pain or warmth at the infusion site.

Serious or Rare Side Effects: - Nephrogenic systemic fibrosis: fibrotic skin and organ changes in patients with severe renal dysfunction. - Severe allergic reaction: anaphylaxis or bronchospasm requiring immediate medical intervention. - Hypotension: sudden drop in blood pressure during or after injection.

Before using Magnevist, clinicians should consider several safety measures. - Renal assessment: evaluate kidney function before administration, especially in patients with chronic kidney disease. - Allergy screening: check for prior reactions to gadolinium agents or iodinated contrast media. - Dose minimization: use the lowest dose necessary for diagnostic quality imaging. - Hypersensitivity caution: avoid in individuals with known gadolinium allergy. - Pregnancy consideration: defer use unless benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Magnevist may interact with other drugs or conditions that affect renal function or contrast efficacy.

Major Interactions (Avoid): - Nephrotoxic agents (e.g., aminoglycosides, high‑dose NSAIDs): increase risk of renal impairment and NSF. - Concurrent administration of other gadolinium or iodinated contrast agents: may amplify toxicity.

Moderate Interactions (Monitor Closely): - Metformin: consider temporary discontinuation in patients with reduced renal function. - Loop diuretics: monitor renal function and fluid balance. - Iron chelation therapy: may reduce contrast enhancement, requiring imaging quality assessment.